Tryngolza approved in EU for severe hypertriglyceridaemia

by | 17th Nov 2026 | News

RNA therapy reduces triglycerides and pancreatitis risk

The European Commission has approved Tryngolza (olezarsen) as an adjunct to diet and other lipid-lowering therapies for adults with severe hypertriglyceridaemia (sHTG) with fasting triglyceride levels of at least 880 mg/dL (10 mmol/L).

The approval makes Tryngolza the first and only RNA-targeted therapy authorised in the EU for patients with sHTG at this threshold. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October and expands the medicine’s existing indication for familial chylomicronaemia syndrome into a broader patient population.

The approval was based on data from the phase 3 CORE and CORE2 studies, sponsored by Ionis Pharmaceuticals and conducted with the TIMI Study Group. A pre-specified analysis of patients with baseline triglyceride levels of at least 880 mg/dL showed the treatment reduced triglyceride levels by up to 73% after six months compared with placebo, with benefits maintained for 12 months.

A pooled analysis of the CORE and CORE2 studies also showed an 83% reduction in adjudicated acute pancreatitis events over 12 months compared with placebo.

Approximately 700,000 people across the EU’s five largest markets are estimated to have triglyceride levels of at least 880 mg/dL and are therefore considered at high risk of developing acute pancreatitis.

Erik S.G. Stroes, Professor of Vascular Medicine at Amsterdam UMC, said: “Acute pancreatitis is a potentially life-threatening medical emergency that may require intensive care admission and prolonged hospitalisation.”

He added: “Some patients experience permanent organ damage and lasting effects on their quality of life. There is an unmet need for patients with sHTG for new, effective therapies to help reduce the risk of acute pancreatitis.”

Lydia Abad-Franch, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi, commented: “The European Commission’s approval of Tryngolza for the treatment of sHTG is an important step forward for patients in Europe who remain at increased risk of acute pancreatitis despite diet and existing lipid-lowering therapies.”

She continued: “The EC decision marks meaningful progress for eligible patients living with sHTG.”

Brett P. Monia, Chief Executive Officer of Ionis, explained: “This approval reflects the potential of RNA-targeted medicines to address serious conditions such as sHTG. We are proud to work with our long-standing partner Sobi to bring Tryngolza to people in need across the EU.”

Tags


Related posts